On August 24, TransEnterix (TRXC) stock closed at $5.37, which represents a ~6.13% growth from its prior day’s close of $5.06. The stock rose 18% over the week to $5.37 on August 24 from its prior week’s close of $4.57 on August 17.
On August 24, TransEnterix closed at $5.37, which is ~12% below its 52-week high of $6.04 on June 27. TransEnterix hit its 52-week low of $0.76 on August 24, 2017.
TransEnterix, a medical device company, is focused on the development of minimally invasive surgical devices with the digitalization of the interface between the surgeon and the patient. TransEnterix’s leading product is the Senhance System.
In the second quarter, TransEnterix reported revenues of $6.4 million, which included sales of four Senhance Sytems. It sold three of them in the EMEA (Europe, the Middle East, and Africa) markets and one in the US market.
TransEnterix has undertaken various initiatives to develop new products. It’s on track with the timeline for the development of those products. In June, the FDA approved its additional Senhance System with a 3-millimeter diameter instrument. TransEnterix is presently launching the ultrasonic energy device and 5-millimeter articulated additional instruments. It anticipates a CE marking for its ultrasonic energy device and articulating instruments by the end of 2018. The CE approvals should help TransEnetrix’s product commercialization in European markets.
Of the five analysts tracking TransEnterx in August, one has recommended a “strong buy,” and one has recommended a “buy.” Three analysts have recommended a “hold.”
On August 26, TransEnterix had a consensus 12-month target price of $5.17, which represents a ~3.72% decline over the next 12 months.
Of the 17 analysts tracking Intuitive Surgical (ISRG) in August, ~65% of them are recommending a “buy” for the stock. Among the five analysts tracking Mazor Robotics (MZOR), one has recommended a “buy,” three have recommended a “hold,” and one has recommended a “sell.”
On August 26, Intuitive Surgical and Mazor Robotics had consensus 12-month target prices of $564.47 and $59.33, respectively, which represent ~4.24% and ~29.01% returns on investment, respectively, over the next 12 months.